Leonteq Securities AG Sells 48,124 Shares of Intellia Therapeutics, Inc. $NTLA

Leonteq Securities AG decreased its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 84.7% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 8,666 shares of the company’s stock after selling 48,124 shares during the period. Leonteq Securities AG’s holdings in Intellia Therapeutics were worth $111,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Oppenheimer & Co. Inc. raised its holdings in Intellia Therapeutics by 0.8% in the 4th quarter. Oppenheimer & Co. Inc. now owns 105,165 shares of the company’s stock valued at $945,000 after acquiring an additional 808 shares during the period. Comerica Bank lifted its position in Intellia Therapeutics by 45.8% during the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock worth $26,000 after acquiring an additional 901 shares during the last quarter. Benjamin Edwards Inc. boosted its holdings in shares of Intellia Therapeutics by 1.8% during the second quarter. Benjamin Edwards Inc. now owns 63,034 shares of the company’s stock worth $591,000 after acquiring an additional 1,126 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in shares of Intellia Therapeutics by 8.4% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 17,250 shares of the company’s stock worth $159,000 after acquiring an additional 1,333 shares during the period. Finally, Ameriprise Financial Inc. grew its position in shares of Intellia Therapeutics by 13.9% in the second quarter. Ameriprise Financial Inc. now owns 11,803 shares of the company’s stock valued at $111,000 after purchasing an additional 1,443 shares during the last quarter. Institutional investors and hedge funds own 88.77% of the company’s stock.

Insiders Place Their Bets

In related news, CAO Michael P. Dube sold 2,641 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $16.78, for a total transaction of $44,315.98. Following the completion of the sale, the chief accounting officer directly owned 66,886 shares in the company, valued at $1,122,347.08. This represents a 3.80% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, EVP Edward J. Dulac III sold 4,677 shares of the firm’s stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total value of $84,186.00. Following the completion of the sale, the executive vice president directly owned 156,286 shares in the company, valued at $2,813,148. This trade represents a 2.91% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 3.50% of the stock is currently owned by insiders.

Intellia Therapeutics Trading Down 2.3%

Shares of Intellia Therapeutics stock opened at $17.43 on Wednesday. The company has a 50 day moving average of $14.25 and a 200-day moving average of $13.19. Intellia Therapeutics, Inc. has a 1-year low of $7.95 and a 1-year high of $28.25. The company has a market cap of $2.44 billion, a PE ratio of -4.92 and a beta of 1.77.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.92) by $0.11. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. The business had revenue of $15.05 million for the quarter, compared to analysts’ expectations of $13.81 million. During the same period last year, the firm posted ($1.10) earnings per share. Research analysts forecast that Intellia Therapeutics, Inc. will post -3.18 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. Wall Street Zen cut Intellia Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Truist Financial raised Intellia Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Leerink Partners set a $35.00 price objective on Intellia Therapeutics in a research report on Monday, April 27th. Chardan Capital lifted their target price on Intellia Therapeutics from $27.00 to $30.00 and gave the stock a “buy” rating in a report on Monday, April 27th. Finally, The Goldman Sachs Group boosted their target price on shares of Intellia Therapeutics from $8.00 to $9.00 and gave the company a “sell” rating in a research report on Tuesday, April 28th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $20.46.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.